Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $725 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $265 |
| Gross Profit | $0 | $0 | $0 | $461 |
| % Margin | – | – | – | 63.5% |
| R&D Expenses | $0 | $0 | $0 | $102 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $1,801 | $1,458 | $1,450 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $991 | $0 | $0 | $8,039 |
| Operating Expenses | $991 | $1,801 | $1,458 | $9,591 |
| Operating Income | -$991 | -$1,801 | -$1,458 | -$9,131 |
| % Margin | – | – | – | -1,258.7% |
| Other Income/Exp. Net | $68 | -$240 | $259 | -$143 |
| Pre-Tax Income | -$923 | -$2,041 | -$1,200 | -$9,273 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$923 | $5,433 | -$2,260 | -$9,273 |
| % Margin | – | – | – | -1,278.4% |
| EPS | -0.022 | -1.29 | -9.37 | -0.13 |
| % Growth | 98.3% | 86.2% | -7,107.7% | – |
| EPS Diluted | -0.022 | -1.29 | -9.37 | -0.13 |
| Weighted Avg Shares Out | 42,285 | 25,923 | 1,162 | 80,260 |
| Weighted Avg Shares Out Dil | 42,285 | 25,923 | 1,162 | 80,260 |
| Supplemental Information | – | – | – | – |
| Interest Income | $67 | $89 | $48 | $25 |
| Interest Expense | $0 | $0 | $0 | $167 |
| Depreciation & Amortization | $708 | $0 | $0 | $667 |
| EBITDA | -$215 | -$1,801 | -$1,458 | -$8,439 |
| % Margin | – | – | – | -1,163.3% |